Xiamen Amoytop Biotech Co Ltd (688278) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Xiamen Amoytop Biotech Co Ltd (688278) has a cash flow conversion efficiency ratio of 0.197x as of September 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥332.29 Million ≈ $48.63 Million USD) by net assets (CN¥1.69 Billion ≈ $247.28 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Xiamen Amoytop Biotech Co Ltd to measure how much of total assets are equity-financed.
Xiamen Amoytop Biotech Co Ltd - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Xiamen Amoytop Biotech Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 688278 operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Xiamen Amoytop Biotech Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Xiamen Amoytop Biotech Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pinnacle Investment Management Group Ltd
AU:PNI
|
0.089x |
|
CleanSpark Inc
NASDAQ:CLSK
|
-0.163x |
|
Group 1 Automotive Inc
NYSE:GPI
|
0.046x |
|
Hang Zhou Iron & Steel Co Ltd
SHG:600126
|
0.124x |
|
NCR Atleos Corporation
NASDAQ:NATL
|
-0.023x |
|
ELF Beauty Inc
NYSE:ELF
|
0.051x |
|
freenet AG
F:FNTN
|
0.064x |
|
Apple Hospitality REIT Inc
NYSE:APLE
|
0.016x |
Annual Cash Flow Conversion Efficiency for Xiamen Amoytop Biotech Co Ltd (2016–2024)
The table below shows the annual cash flow conversion efficiency of Xiamen Amoytop Biotech Co Ltd from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see 688278 company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥2.55 Billion ≈ $373.63 Million |
CN¥430.63 Million ≈ $63.02 Million |
0.169x | -38.20% |
| 2023-12-31 | CN¥1.88 Billion ≈ $274.58 Million |
CN¥512.10 Million ≈ $74.94 Million |
0.273x | +5.78% |
| 2022-12-31 | CN¥1.41 Billion ≈ $205.98 Million |
CN¥363.16 Million ≈ $53.14 Million |
0.258x | +27.61% |
| 2021-12-31 | CN¥1.16 Billion ≈ $169.93 Million |
CN¥234.78 Million ≈ $34.36 Million |
0.202x | +118.40% |
| 2020-12-31 | CN¥1.00 Billion ≈ $146.39 Million |
CN¥92.61 Million ≈ $13.55 Million |
0.093x | -57.69% |
| 2019-12-31 | CN¥563.55 Million ≈ $82.47 Million |
CN¥123.30 Million ≈ $18.04 Million |
0.219x | +22.53% |
| 2018-12-31 | CN¥499.26 Million ≈ $73.06 Million |
CN¥89.15 Million ≈ $13.04 Million |
0.179x | +856.57% |
| 2017-12-31 | CN¥483.26 Million ≈ $70.72 Million |
CN¥-11.41 Million ≈ $-1.67 Million |
-0.024x | -126.59% |
| 2016-12-31 | CN¥478.09 Million ≈ $69.96 Million |
CN¥42.43 Million ≈ $6.21 Million |
0.089x | -- |
About Xiamen Amoytop Biotech Co Ltd
Xiamen Amoytop Biotech Co., Ltd. engages in research, development, production, and sale of recombinant protein drugs in China. The company provides solutions for diseases, such as viral hepatitis, malignant tumors, and immunotherapy. Xiamen Amoytop Biotech Co., Ltd. was founded in 1996 and is based in Xiamen, China.